Leaving clinical risk behind
Positive data from the two Phase III trials in Lennox-Gastaut syndrome (LGS) patients, coupled with the previously announced positive Dravet syndrome Phase III, seem to indicate that Epidiolex (cannabidiol or CBD) works across different seizure disorders. This increases our confidence in the Phase III programs for tuberous sclerosis complex (TSC) and infantile spasms (IS). A single NDA filing for both LGS and Dravet is expected mid-2017 with a launch in mid-2018.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.